Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Mogrosides for Delayed-Onset Muscle Soreness

17 de septiembre de 2026 actualizado por: Jingzhi Zhang, Guangxi Normal University

Effects of Mogroside Intervention on the Levels of Delayed-Onset Muscle Soreness-Related Indicators

This study will examine whether taking mogrosides, natural compounds found in monk fruit, affects delayed-onset muscle soreness (DOMS) and related markers of muscle damage, inflammation, oxidative stress, and muscle function after strenuous exercise. The study will also explore whether changes in the body's antioxidant capacity are related to changes in DOMS-related measures.

The study plans to enroll 16 healthy young male students. Participants will be randomly assigned to a control group (n=8) or an experimental group (n=8). The control group will receive a placebo, and the experimental group will receive mogrosides. Participants will take their assigned product by mouth for 27 days, perform a standardized frog-jump training session, and then continue taking the assigned product for 3 more days.

Researchers will measure subjective muscle soreness using a visual analog scale (VAS) at baseline before supplementation, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. At these same time points, they will also measure serum creatine kinase (CK) and creatine kinase isoenzyme MM (CK-MM) activity, total antioxidant capacity (T-AOC), malondialdehyde (MDA), plasma interleukin-6 (IL-6), thigh circumference at the junction of the middle and lower thirds of the thigh, maximal isometric strength for lifting the thigh, and active range of motion (AROM) of the knee.

The study will assess the effects of mogroside supplementation on DOMS severity and on changes in muscle damage, inflammation, oxidative stress, and muscle function. It will also explore whether improved antioxidant capacity is related to changes in DOMS-related indicators. This study is not yet recruiting participants.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

16

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jingzhi Zhang
  • Número de teléfono: +86 16677137704
  • Correo electrónico: 170787717@qq.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 23 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  • Male, aged 20 to 23 years.
  • Healthy, with no history of major diseases or severe injuries.
  • Physical fitness level comparable to that of an ordinary physical education/sports student.
  • No training or competition obligations during the study period.
  • Provides informed consent for the study protocol.

Exclusion Criteria:

  • History of musculoskeletal injury within the past 2 months.
  • Use of anti-inflammatory drugs or steroid medications within the past 1 month.
  • Use of antioxidant medications such as vitamin E or vitamin C within the past 1 month.
  • Use of any other medications within the past 2 weeks.
  • Participation in strenuous exercise within the past 10 days.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Mogroside

Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity >95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity >95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Comparador de placebos: Placebo

Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Muscle Soreness Assessed by Visual Analog Scale (VAS)
Periodo de tiempo: From enrollment to the end of treatment at 30 days

Subjective muscle soreness will be assessed at six time points: before the first dose of study product, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. A 10-cm VAS ruler will be used. The side facing the participant is marked 0 at one end ("no pain") and 10 at the other ("worst imaginable pain"). Participants will move a cursor to indicate their current level of muscle soreness. The distance from the "no pain" end to the mark will be recorded as the pain score in centimeters. Higher scores indicate greater muscle soreness.

From enrollment to the end of treatment at 30 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Active Range of Motion (AROM) of the Knee
Periodo de tiempo: From enrollment to the end of treatment at 30 days

Bilateral active knee range of motion will be measured with a joint angle goniometer at six time points: before the first dose, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. Participants will lie prone with both lower limbs extended, together, and relaxed. The goniometer axis will be placed at the lateral femoral condyle, the fixed arm along the middle of the femur, and the moving arm along the fibula. Participants will actively flex the lower leg as much as possible. The arc from the starting position to the final position of the lower leg will be recorded in degrees.

From enrollment to the end of treatment at 30 days
Maximal Isometric Muscle Force for Lifting the Thigh
Periodo de tiempo: From enrollment to the end of treatment at 30 days

Bilateral maximal isometric muscle force will be measured with a MicroFET2 handheld dynamometer at six time points: before the first dose, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. Participants will sit on the examination bed with arms at their sides, legs relaxed, and lower legs hanging vertically. The tester will place the dynamometer over the distal quadriceps on the front of the thigh. Participants will push the thigh upward against the tester and maintain the contraction for 8 seconds. The test will be repeated 5 times, and the maximum value will be recorded.

From enrollment to the end of treatment at 30 days
Thigh Circumference at the Junction of the Middle and Lower Thirds
Periodo de tiempo: From enrollment to the end of treatment at 30 days

Bilateral thigh circumference will be measured with a soft tape measure at six time points: before the first dose, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. Participants will lie prone on the examination bed. The circumference will be measured at the junction of the middle and lower thirds of the line between the greater trochanter of the femur and the lateral condyle. The measurement point will be marked after the first measurement to ensure the same location is used at later time points. Results will be recorded in centimeters.

From enrollment to the end of treatment at 30 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

19 de septiembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2026

Finalización del estudio (Estimado)

1 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

17 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de septiembre de 2026

Publicado por primera vez (Actual)

23 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • GXNU20260903003

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .